HER2‑Positive Breast Cancer
Breast cancer is not a single disease—it includes several subtypes that behave differently and respond to different treatments. One important subtype is HER2-positive breast cancer, a form driven by high levels of a specific protein that promotes cancer growth.
Advances in targeted therapies have significantly improved outcomes for people diagnosed with HER2-positive breast cancer. Understanding what this diagnosis means can help patients and families feel more informed and empowered when discussing care options with healthcare professionals.
Overview / Definition
HER2-positive breast cancer is a type of breast cancer characterized by overexpression of a protein called human epidermal growth factor receptor 2 (HER2).
What is HER2?
HER2 is a protein found on the surface of some cells. It plays a role in:
- Cell growth
- Cell division
- Cell repair
In normal cells, HER2 helps regulate healthy cell growth. However, in HER2-positive breast cancer:
- The HER2 gene is amplified (there are too many copies), or
- The HER2 protein is overproduced, leading to uncontrolled cell growth.
Approximately 15–20% of breast cancers are HER2-positive. Historically, these cancers tended to grow faster and were more aggressive. Today, targeted therapies have significantly improved survival rates and reduced recurrence.
Causes and Risk Factors
The exact cause of HER2-positive breast cancer is not fully understood. However, it develops due to genetic changes in breast cells that occur over time.
Known Risk Factors for Breast Cancer (General)
While HER2 positivity itself does not have clearly defined independent risk factors, overall breast cancer risk increases with:
- Increasing age
- Family history of breast or ovarian cancer
- Inherited genetic mutations (e.g., BRCA1/BRCA2)
- Early menstruation (before age 12)
- Late menopause
- Hormone replacement therapy
- Alcohol use
- Obesity, particularly after menopause
Importantly, HER2-positive breast cancer is not inherited in most cases, though research continues into genetic influences.
Symptoms or Clinical Presentation
The symptoms of HER2-positive breast cancer are generally similar to other forms of breast cancer.
Common Symptoms Include:
- A new lump or thickening in the breast or underarm
- Changes in breast size or shape
- Skin dimpling or puckering (sometimes resembling an orange peel)
- Nipple inversion
- Nipple discharge (especially if bloody)
- Redness, scaliness, or irritation of the breast skin
HER2-positive cancers may grow and spread more rapidly than some other subtypes, making early detection particularly important.
Diagnosis and Screening
Screening
Routine breast cancer screening helps detect cancer early, often before symptoms develop.
- Mammography is the primary screening tool.
- Breast MRI may be recommended for high-risk individuals.
Diagnostic Testing
If breast cancer is suspected, the following steps are commonly taken:
- Imaging tests
- Diagnostic mammogram
- Breast ultrasound
- MRI (in selected cases)
- Biopsy
A sample of tissue is removed and examined under a microscope. - HER2 Testing
All diagnosed breast cancers are tested for HER2 status using:- Immunohistochemistry (IHC) – measures HER2 protein levels
- Fluorescence in situ hybridization (FISH) – detects HER2 gene amplification
HER2 status is critical because it determines eligibility for targeted therapies.
Treatment and Management Options
The treatment plan for HER2-positive breast cancer depends on:
- Cancer stage
- Tumor size
- Lymph node involvement
- Hormone receptor status
- Patient’s overall health
Treatment is often multimodal, meaning several therapies are combined.
1. Targeted Therapy (Key Feature of HER2-Positive Treatment)
Targeted treatments specifically block HER2 activity. These have dramatically improved outcomes.
Common targeted medications include:
- Trastuzumab (Herceptin)
- Pertuzumab (Perjeta)
- Ado-trastuzumab emtansine (T-DM1)
- Fam-trastuzumab deruxtecan
- Tyrosine kinase inhibitors (e.g., tucatinib, lapatinib)
These drugs interfere with HER2 signaling and help slow or stop tumor growth.
2. Chemotherapy
Often used in combination with targeted therapy, especially in:
- Early-stage disease (before or after surgery)
- Advanced or metastatic cancer
Chemotherapy may be given:
- Neoadjuvant (before surgery, to shrink tumors)
- Adjuvant (after surgery, to reduce recurrence risk)
3. Surgery
Options include:
- Lumpectomy (breast-conserving surgery)
- Mastectomy (removal of the breast)
- Sentinel lymph node biopsy or axillary lymph node dissection
The choice depends on tumor size, location, and patient preference.
4. Radiation Therapy
Radiation is often recommended after:
- Lumpectomy
- Certain mastectomy cases with lymph node involvement
It reduces the risk of local recurrence.
5. Hormone Therapy (If Applicable)
Some HER2-positive cancers are also hormone receptor-positive. In such cases, endocrine therapy (e.g., tamoxifen or aromatase inhibitors) may be included.
Prognosis
Before targeted therapies, HER2-positive breast cancer was associated with poorer outcomes. Today:
- Survival rates have improved significantly
- Recurrence risk has decreased
- Many patients achieve long-term remission
Prognosis depends on:
- Stage at diagnosis
- Response to therapy
- Overall health
Prevention and Lifestyle Considerations
There is no guaranteed way to prevent HER2-positive breast cancer. However, general strategies may reduce overall breast cancer risk:
- Maintain a healthy body weight
- Engage in regular physical activity
- Limit alcohol intake
- Avoid smoking
- Breastfeed when possible
- Participate in recommended screening programs
For individuals with a strong family history, genetic counseling may be helpful.
Living With HER2-Positive Breast Cancer
Improvements in therapy have transformed HER2-positive breast cancer into a highly treatable condition. Ongoing follow-up care is essential to:
- Monitor for recurrence
- Manage treatment side effects
- Support emotional and mental well-being
Support groups, counseling, and survivorship programs can provide valuable resources and community connection.
Conclusion
HER2-positive breast cancer is a biologically distinct subtype characterized by overexpression of the HER2 protein, which promotes rapid cancer cell growth. While once considered highly aggressive, advances in targeted therapies have dramatically improved survival and treatment outcomes.
Early detection, accurate HER2 testing, and personalized treatment strategies are critical components of effective care. With modern medicine, many individuals diagnosed with HER2-positive breast cancer go on to live full, healthy lives.
Disclaimer:
This article is intended for educational purposes only and does not substitute for professional medical advice. If you have concerns about breast cancer or your personal risk, please consult a qualified healthcare professional for individualized evaluation and care.
